Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Reexamination Certificate
2011-06-07
2011-06-07
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
C560S034000, C548S250000, C548S251000, C514S381000, C514S562000, C514S563000, C514S564000
Reexamination Certificate
active
07956216
ABSTRACT:
Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.
REFERENCES:
patent: 4016282 (1977-04-01), Konig et al.
patent: 4298605 (1981-11-01), Oi et al.
patent: 2003/0195209 (2003-10-01), Dellaria et al.
patent: 2004/0152743 (2004-08-01), Schoenafinger et al.
RN 106135-34-6, 1987.
Carter et al, John Wiley & Sons, Chemotherapy of Cancer, 1981, 362-365.
Driver, et al., “Further Studies on Bisnorpenicillins”, The Journal of Antibiotics, Apr. 1985, pp. 550-553, vol. 38, No. 4.
Ohi, et al., “Semisynthetic B-Lactam Antibiotics. IV. Synthesis and Antibacterial . . . or Its Acetate”, Chem. Pharm. Bull., 1987, pp. 1903-1909, vol. 35 (5).
Ohi, et al “Semisynthetic B-Lactam Antibiotics I. Synthesis and Antibacterial . . . Catechol Moieties”, The Journal of Antibiotics, Feb. 1986, pp. 230-241, vol. 39 (2).
Chugai Pharmaceutical KK, Alpha-benzoyl:ureido:phenylacetic acid cpds . . . antimicrobial penicillin(s), Abstract, pp. 1-2.
Adams, et al., “Highly Specific in Vivo Tumor Targeting by Monovalent . . . Sincle-Chain Fv1”, Cancer Research, 1993, pp. 4026-4034, vol. 53.
Baell, et al., “Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs”, Biochemical Pharmacology, 2002, pp. 851-863, vol. 64.
Bouillet, et al., “Degenerative Disorders Caused by Bcl-2 Deficiency Prevented by Loss of Its BH3-Only antagonist Bim”, Developmental Cell, 2001, pp. 645-653, vol. 1.
Brewis, et al., “Particle Assembly Incorporating a VP22-BH3 Fusion Protein . . . and Apoptosis”, Molecular Therapy, 2003, pp. 262-270, vol. 7 (2).
Cory, et al., “The BCL2 Family: Regulators of the Cellular Life-or-Death Switch”, Nature Reviews/Cancer, 2002, pp. 647-655, vol. 2.
Cumber, et al., “Comparative Stabilities in Vitro and In Vivo of a Recombinant . . . and a bisFvCys Conjugate”, The Journal of Immunology, 1992, pp. 120-126, vol. 149.
Davies, et al., “‘Camelising’” human antibody fragments: NMR studies on VH domains, FEBS Letters, 1994, pp. 285-290, vol. 339.
Dearden, “Monolclonal Antibody Therapy of Haematological Malignancies”, Therapy Review, Bic drugs, 2002, pp. 283-301, vol. 16(4).
Dunican, et al., “Designing Cell-Permeant Phosphopeptides to Modulate Intracellular Signaling Pathways”, Biopolymers (Peptide Science), 2001, pp. 45-60, vol. 60.
Dharap, et al., “Targeted Proapoptotic LHRH-BH3 Peptide”, Pharmaceutical Research, 2003, pp. 889-896, vol. 20 (6).
Galfre, et al., “Antibodies to major histocompatibility antigens produced by hybrid cell lines”, Nature, 1977, pp. 550-552, vol. 266.
Glockshuber, et al., “A Comparison of Strategies to Stabilize Immunoglobulin Fv-Fragments”, Biochemistry, 1990, pp. 1362-1367, vol. 29.
Goulet, et al., “Conjugation of Blocked Ricin to an Anti-CD19 Monoclonal Antibody . . . and CD19 Internalization”, Blood, 1997, pp. 2364-2375, vol. 90(6).
Hamers-Casterman, et al., “Naturally occurring antibodies devoid of light chains”, Nature, 1993, pp. 446-448, vol. 363.
Jue, et al., “Addition of Sulfhydryl Groups to Escherichia . . . (Methyl 4-Mercaptobutyrimidate)”, Iminothiolane Modification of Ribosomes, 1978, pp. 5399-5406, vol. 17(25).
Kohler, et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, 1975, pp. 495-497, vol. 256.
Kostelny, et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers”, The Journal of Immunology, 1992, pp. 1547-1553, vol. 148(5).
Krebber, et al., “Reliable cloning of functional antibody variable domains from hybridomas . . . phage display system”, Journal of Immunological Methods, 1997, pp. 35-55, vol. 201.
Ku, et al., “Alternate Protein Frameworks for Molecular Recognition”, Proc. Natl. Acad. Sci., 1995, pp. 6552-6556, vol. 92.
Letai et al., “Distinct BH3 domains either sensitize or activate mitochondrial . . . cancer therapeutics”, Cancer Cell, 2002, pp. 183-192, vol. 2.
Ludwig, et al., “Monoclonal antibody therapeutics and apoptosis”, Oncogene, 2003, pp. 9097-9106, vol. 22.
Marks, et al., “Targeted Therapy with an Amphipathic . . . Lymphocytic Leukemia Cells”, Blood, 2003, pp. 1, vol. 247.
Pack et al, “Miniantibodies: Use of Amphipathis Helices . . . with High Avidity inEscherichia coli”, Biochemistry, 1992, pp. 1579-1584, vol. 31.
Patani, et al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev., 1996, pp. 3147-3176, vol. 96.
Petros, et al., Rationale for Bcl-Xl/Bad Peptide Complex Formation from Structure, Mutagenesis, and Biophysical Studies, Protein Science, 2000, pp. 2528-2534, vol. 9.
Reiter, et al., “Improved Binding and Antitumor Activity of a Recombinant . . . of the Fv Fragment”, The Journal of Biological Chemistry, 1994, pp. 18327-18331, vol. 26(28).
Reiter, et al., “Stabilization of the Fv Fragments in Recombinant Immunotixins . . . Framework Regions”, Biochemistry, 1994, pp. 5451-5459, vol. 33.
Reiter, at al., “Antitumor Activity and Pharmacolienetics in Mice of a . . . Disulfide-stabilized Fv Fragments”, Cancer Research, 1994, pp. 2714-2718, vol. 54.
Sapra, et al., “Internalizing Antibodies Are Necessary for Improved . . . of Antibody-targeted Liposomal Drugs”, Cancer Research, 2002, pp. 7190-7194, vol. 62.
Sattler, et al., Structure of Bcl-xl-Bak Peptide Complex: . . . Regulators of Apoptosis, Science, 1997, pp, 983-986, vol. 275.
Schimmer, et al., The BH3 domain of BAD fused to the Antennapedia peptide . . . independent of Bcl-2, Cell Death and Differnitation, 2001, pp. 725-733, vol. 8.
Shangary, et al., “Peptides Derived from BH3 of Bcl-2 Family Members: A comparative . . . and activation of Cell Death”, Biochemistry, 2002, pp. 9485-9495, vol. 41.
Snyder, et al., Treatment of Terminal Peritoneal Carcinomatosis by a . . . p53-Activating Peptide, PLOS Biology, 2004, pp. 0186-0193, vol. 2(2).
Thorpe, et al., “New Coupling Agents for the Synthesis fo Immunotixins . . . with Improved Stability in Vivo”, Cancer Research, 1987, pp. 5924-5931, vol. 47.
Uckun, et al., “Biotherapy of B-cell percursor leukemia by targeting genistein to . . . kinases” , Science, 1995, pp. 886-891, vol. 267.
Wang, et al., “Polyspermine-Ribonuclease Prepared by Cross-linkage with Dimethyl Suberimidate”, Biochemistry, 1977, pp. 2937-2942, vol. 16(13).
Wang, et al., “Generation and Characterization of an Anti-CD19 Single-Chain . . . disulfide-Linked dgRTA”, Bioconjugate Chem., 1997, pp. 878-884, vol. 8.
Wang, et al., “Cell Permeable Bcl-2 Binding Peptides: A Chemical . . . Induction in Tumor Cells”, Cancer Research, 2000, pp. 1498-1502, vol. 60.
Ward, et al., “Binding Activities of a Repertoire of Single Immunoglobulin . . . fromEscherichia coli”, Letter to Nature, 1989, pp. 544-546, vol. 341.
Webber, et al., “Preparation and Characterization of a Disulfide-Stabilized . . . its Single-Chain Analog”, Molecular Immunology, 1995, pp. 249-258, vol. 32(4).
Worrell, et al., “Effect of Linkage Variation on Pharmacokinetics of Ricin . . . Conjugates in Normal Rats”, Anti-Cancer Drug Design, 1986, pp. 179-188, vol. 1.
Yin, at al., “Terephthalamide Derivatives as Mimetics of . . . Target Bcl-xL Protein”, Bioorganic & Medicinal Chemistry Letters, 2004, pp. 1375-1379, vol. 14.
Yoshitake,
Baell Jonathan
Lessene Guillaume Laurent
Kumar Shailendra
Perkins Coie LLP
The Walter and Eliza Hall Institute of Medical Research
LandOfFree
Alpha-helical mimetics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-helical mimetics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-helical mimetics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2644800